We have also demonstrated in a preclinical model of KRAS-induced lung cancer with loss of p53 that IKKβ inhibition therapy is safe in mice and, even though it is not curative, it shows efficacy in slowing tumor growth. The gene discussed is KRAS; the disease is lung cancer.